search Created with Sketch.

Therapeutics Update

Therapeutics Update

Revisiting Risk

It is time to take a fresh look at carbonic anhydrase inhibitors and sulfonamide allergy.

Jeff Martow, MDCM, FRCSC; Evan Martow, BMSc, MDCM; and Mattan Lustgarten, BSc

Therapeutics Update

Rho Kinase/Norepinephrine Transporter Inhibition for the Treatment of Glaucoma and Ocular Hypertension

An update on the clinical development of a new class of drugs.

Jason Bacharach, MD

Therapeutics Update

Update on Sustained-Release Drug Therapies

These therapies have the potential to change the glaucoma treatment paradigm.

Jonathan S. Myers, MD, and Scott J. Fudemberg, MD

Therapeutics Update

How to Improve Adherence

Try one or all of these tips to help patients understand their treatment plan.

Fiaz Zaman, MD

Therapeutics Update

Adding Insult to Injury

The contribution of systemic medication to dry eye disease.

Sejal R. Amin, MD, and Christopher T. Hood, MD

Therapeutics Update

Generic Versus Branded Glaucoma Drugs

Generic medications offer therapeutic benefits for some patients.

Marcos Reyes, MD, and Lauren Wiggins, MD

Therapeutics Update

Why Are There Not More Pharmacotherapies for Glaucoma?

There is plenty of interest but relatively few drugs in advanced-stage development.

Gary D. Novack, PhD

Therapeutics Update

Discovering the Root Cause of Dry Eye Symptoms

In-office technologies aid clinicians' diagnosis and treatment of DED.

Howard Barnebey, MD

Therapeutics Update

Novel Risk Factors for Glaucoma

Research suggests that many issues other than IOP may play a role in the pathophysiology of glaucoma.

Shan Lin, MD

Therapeutics Update

Glaucoma Associated With Therapies for Psychiatric Disorders

Treatments for some mental illnesses can cause or exacerbate glaucoma.

Julia Song, MD

Therapeutics Update

Fixed-Combination Medical Therapy for Glaucoma

Three surgeons discuss the clinical scenarios in which they prescribe these drugs.

L. Jay Katz, MD; Robert J. Noecker, MD, MBA; and James C. Tsai, MD, MBA

Therapeutics Update

Anterior Segment Ophthalmic Pharmaceuticals

The future is awesome.

F. Fallon Ukpe, MD, MBA, and Jai G. Parekh, MD, MBA

Therapeutics Update

Early Testing of CNTF for Glaucoma

Based on the results of preclinical studies, this neurotrophic factor is a candidate for clinical use.

Keiichiro Iwao, MD, PhD, and Jeffrey L. Goldberg, MD, PhD

Therapeutics Update

A Medical Approach to Forming a Complete Eyelid Crease

Topical prostaglandins may be a viable nonsurgical option for Asian patients who desire a double eyelid crease.

Julia Song, MD

Therapeutics Update

Benzalkonium Chloride and Glaucoma Management Today

Many patients' tolerability to medications can improve with aggressive treatment of ocular surface disease.

Steven T. Simmons, MD

Therapeutics Update

Why Human Tissue Is Essential to Glaucoma Research

Donor eyes provide key insights into the pathophysiology of primary open-angle glaucoma.

Abbot F. Clark, PhD

Therapeutics Update

Iridocorneal Endothelial Syndrome: Keys to Diagnosis and Management

A common pathological mechanism explains the corneal, iris, and angle abnormalities that result in a rare but important type of secondary angle-closure glaucoma.

Matthew D. Lazzara, MD, and Angelo P. Tanna, MD

Therapeutics Update

An Approach to Glaucoma Treatment in Pregnant and Lactating Women

Minimize medications and dosing frequency to limit the risks to the mother, fetus, and breastfed infant.

Pradeep Y. Ramulu, MD, MHS, PhD, and Sarwat Salim, MD

Therapeutics Update

Should You Fire Your Patients for Poor Aherence?

A systematic approach to glaucoma adherence is needed.

Robert M. Kinast, MD, and Steven L. Mansberger, MD, MPH

Therapeutics Update

Are You Confused by Pharmacokinetic Speak?

Concepts in pharmacokinetics are applied in practical ways to the management of ocular infections. However, the selection of bacterial minimum inhibitory concentrations that are artificially low may skew certain parameters used to predict antibacterial efficacy.


View more